Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances of IDH1 mutant inhibitor in cancer therapy
Wangqi Tian, Weitong Zhang, Yifan Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making
Renumathy Dhanasekaran, Hiroyuki Suzuki, L Lemaître, et al.
Hepatology (2023)
Closed Access | Times Cited: 23
Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives
Francesca Carosi, Elisabetta Broseghini, Laura Fabbri, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2752-2752
Open Access | Times Cited: 9
Mutant IDH in Gliomas: Role in Cancer and Treatment Options
Georgios Solomou, Alina Finch, Asim Asghar, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2883-2883
Open Access | Times Cited: 16
The Tricarboxylic Acid Cycle Metabolites for Cancer: Friend or Enemy
Jie Wu, Nian Liu, Jing Chen, et al.
Research (2024) Vol. 7
Open Access | Times Cited: 5
Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway
Cheng-Wu Zhang, Yuanhong Zhou, Tao Chen, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
Weihuan Shao, Yiran Yao, Ludi Yang, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Oncometabolites in cancer: from cancer cells to the tumor microenvironment
Luoyi Chen, Min Huang
Holistic Integrative Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 4
HNF4α inhibits the malignancy of intrahepatic cholangiocarcinoma by suppressing the Wnt signaling pathway
Binghe Xu, Chenbo Ding, Yilong Liu, et al.
Translational Oncology (2025) Vol. 53, pp. 102290-102290
Closed Access
Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Ximu Sun, Han Zhou, Yanming Li, et al.
Future Journal of Pharmaceutical Sciences (2025) Vol. 11, Iss. 1
Open Access
Experience of Next-Generation Sequencing in urothelial carcinoma specimens with panel for 523 genes
Ya. V. Gridneva, D. N. Khmelkova, М. И. Волкова, et al.
Journal of Modern Oncology (2025) Vol. 26, Iss. 4, pp. 489-494
Open Access
Targeting IDH1 mutation-driven Nrf2 signaling to suppress malignant behavior in fibrosarcoma cells
Seoyeon Park, Kyung‐Soo Chun, Do‐Hee Kim
Toxicological Research (2025)
Closed Access
Molecular characterization of colorectal cancer (CRC) using next generation sequencing (NGS) in bridging the gap between research and clinical practice: from biomarker discovery to clinical implementation
Hafeez Abiola Afolabi, Md Salzihan Md Salleh, Zaidi Zakaria, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
The dual role of citrate in cancer
Philippe Icard, Luca Simula, Grit Zahn, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 188987-188987
Open Access | Times Cited: 9
Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy
Fikriye Ozgencil, Habibe Beyza Gunindi, Gökçen Eren
Bioorganic Chemistry (2024) Vol. 149, pp. 107509-107509
Closed Access | Times Cited: 3
Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors—Recent Advances, Challenges and Future Prospects
Adrian Kowalczyk, Julia Zarychta, Monika Lejman, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7916-7916
Open Access | Times Cited: 3
Precision medicine in AML: overcoming resistance
Samuel Urrutia, Koichi Takahashi
International Journal of Hematology (2024) Vol. 120, Iss. 4, pp. 439-454
Closed Access | Times Cited: 3
The iron chelator and OXPHOS inhibitor VLX600 induces mitophagy and an autophagy-dependent type of cell death in glioblastoma cells
Lisa Reisbeck, Benedikt Linder, Georg Tascher, et al.
AJP Cell Physiology (2023) Vol. 325, Iss. 6, pp. C1451-C1469
Open Access | Times Cited: 8
Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
Felix Neumaier, Boris D. Zlatopolskiy, Bernd Neumaier
Molecules (2023) Vol. 28, Iss. 7, pp. 2890-2890
Open Access | Times Cited: 7
Tubulocystic Carcinoma of Bile Ducts
Francesca Masetto, Andrea Mafficini, Burcu Saka, et al.
The American Journal of Surgical Pathology (2024) Vol. 48, Iss. 9, pp. 1082-1092
Closed Access | Times Cited: 2
Melanoma genomics – will we go beyond BRAF in clinics?
Justyna Mirek, Wiesław Bal, Magdalena Olbryt
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 9
Open Access | Times Cited: 2
Olutasidenib: A ray of hope in the treatment of acute myeloid leukaemia
Bhupender Nehra, Manoj Kumar, Sumitra Singh, et al.
Health Sciences Review (2023) Vol. 7, pp. 100100-100100
Open Access | Times Cited: 6
Current Approaches to Epigenetic Therapy
Ekaterina D. Griazeva, Д. М. Федосеева, Elizaveta I. Radion, et al.
Epigenomes (2023) Vol. 7, Iss. 4, pp. 23-23
Open Access | Times Cited: 6
Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy
Karen E. Schoedel, Tanya Heim, Anette Duensing, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 247-247
Open Access | Times Cited: 1
Advancing the Management of Skull Base Chondrosarcomas: A Systematic Review of Targeted Therapies
Edoardo Agosti, Marco Zeppieri, Sara Antonietti, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 3, pp. 261-261
Open Access | Times Cited: 1
Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations
Weitong Zhang, Hailong Bai, Yifan Wang, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 336-336
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top